Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Oncothyreon Canada Inc.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histopathologically confirmed breast cancer
Documented Stage IV disease
Estrogen and/or progesterone-receptor positive
Stable disease on aromatase inhibitor or Faslodex® treatment begun at least 12 weeks prior to enrolment
Performance status, ECOG = 0 or 1
Life expectancy \> 12 weeks
History of freedom from progression for at least 6 months following surgery with a curative intent or for at least 6 months during adjuvant chemotherapy, adjuvant radiotherapy or adjuvant hormonal therapy such as tamoxifen/toremifene treatment
No radiotherapy or major surgery within 4 weeks prior to enrolment
You may not be if
Pregnant or lactating
Known brain metastasis
Bone marrow involvement as the only site of metastasis
First line chemotherapy for Stage IV disease
Past or current cancer other than breast cancer, except for curatively treated basal cell cancer or in situ cancer of the cervix with no evidence of disease
Autoimmune disease, e. g., type I juvenile onset diabetes mellitus, antibody positive rheumatoid arthritis, Grave's disease, lupus, Crohn's disease, IBD, Hashimoto's thyroiditis
Known intercurrent infections (including HBV or HCV) or immunosuppression \[human immunodeficiency virus (HIV) or other conditions\] or clinical evidence of these conditions
Other significant active infection
Pleural effusions and/or ascites requiring paracentesis every 2 weeks or more frequently
Splenectomy
Concurrent treatment with chemotherapeutic agents other than low-dose cyclophosphamide used in this study
Treatment with interferons (IFNs), cytokines, systemic steroids or other biologicals within 4 weeks prior to enrolment
Receipt of another investigational drug within 30 days of enrolment
